<!DOCTYPE html>
<html>
<head></p>
</head>
<style>
  h1{
      color:orange;
      font-size: 50px;
  }

  h3{ 
      color:lightseagreen;
      font-size: 70px
  }

  .para{
    background-color: azure;
    border: 15px solid lightblue;
    padding: 10px;
    margin: 20px
}

  </style>

  <body>
    <h1><strong>Recent Frequently Asked Questions (FAQs)</strong></h1>
      <p class="intro">There are some common problems about COVID-19 or about the vaccine, here are the answers below.</p>
      

<h3>Privacy Concern of “LeaveHomeSafe” mobile app </h3>
     <p class="para">The "LeaveHomeSafe" mobile app is a digital tool for fighting against the epidemic. Protection of personal privacy has always been the prime objective in the app's design, development and use. No registration is required and all data related to personal privacy stored in the app are masked and encrypted. 
      <br>
      <br>
      In addition, the OGCIO has repeatedly explained in response to the allegations related to the facial recognition module in May this year. "LeaveHomeSafe" mobile app has<strong> never</strong> used nor requires any facial recognition function. The relevant facial recognition module has also been removed already as pledged.
     </p>

<h3>Safety Concern of COVID-19 vaccines</h3>
     <p class="para"> The Government stressed that COVID-19 vaccines used in Hong Kong must satisfy the relevant requirements and procedures, and obtain emergency use approval in accordance with the Prevention and Control of Disease (Use of Vaccines) Regulation (Cap. 599K) (the Regulation), with a view to ensuring the safety, efficacy and quality of the vaccines.
      <br>
      <br>
      According to the Regulation, the Secretary for Food and Health may, under the state of public health emergency, authorise the use of COVID-19 vaccines which fulfil the criteria of safety, efficacy and quality for the purpose of vaccination programmes conducted by the Government. The Regulation also specifies the conditions and procedures which the vaccine manufacturer or its representative, importer, or wholesale dealer must follow when submitting application for seeking authorisation for emergency use. In particular, the applicant must submit Phase 3 clinical data of the vaccine concerned, overseas authorisation obtained, and other information relevant to the safety, efficacy and quality of the vaccine. The Advisory Panel appointed by the Chief Executive under the Regulation will examine the information of relevant vaccine and provide a clear recommendation to the Government. The Secretary for Food and Health will consider the advice of the Advisory Panel before authorising a vaccine for emergency use.
      <br>
      <br>
      Therefore, the vaccines used in Hong Kong is safe and effective.
     </p>

<h3>Privacy Concern on Specimens of Universal Community Testing Programme </h3>
     <p class="para">The Universal Community Testing Programme (the Programme) would only do testing on the COVID-19 virus. All testing will be conducted in Hong Kong. Specimens will not be transported outside Hong Kong and will be destroyed after testing. 
      <br>
      <br>
      Under the Programme, specimens and the registration of personal particulars will be handled separately. Privacy will not be compromised. 
      <br>
      <br>
       No personal particulars will be indicated on the sampling bottles of the Programme. The testing agencies will know only the serial numbers but not the identity of specimen owners. 
      <br>
      <br>
      Personal data of participants who join the Programme on a voluntary basis will be encrypted and stored in the servers within the Government data centre. The data will only be available to the Department of Health or relevant departments for the purpose of disease control and be handled in accordance with the provisions of the Personal Data (Privacy) Ordinance (Cap. 486).  The data will not be transferred outside Hong Kong. All personal data and testing results will be disposed of within one month after the completion of the Programme.
     </p>

  </body>

</html>


